CJC-1295 vs Icotrokinra
Overview
CJC-1295 is primarily a performance & growth peptide, while Icotrokinra is used for immune support.
This page compares CJC-1295 and Icotrokinra across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| CJC-1295 | Icotrokinra | |
|---|---|---|
| Category | Performance & Growth | Immune Support |
| Regulatory status (US) | Research use only | FDA approved |
| Typical dosage | 1-2 mg | — |
| Frequency | weekly | — |
| Reported benefits | Increased muscle mass, fat loss, improved recovery, better sleep, enhanced bone density | — |
| Reported side effects | Water retention, joint pain, potential insulin resistance with prolonged use | — |
Key differences
Primary use. CJC-1295 is categorised under Performance & Growth, while Icotrokinra falls under Immune Support. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. CJC-1295: not FDA-approved; treated as a research compound. Icotrokinra: FDA-approved.
Dosing. CJC-1295 is typically dosed at 1-2 mg (weekly). Typical dosing for Icotrokinra is not catalogued.
Can you stack them?
Some protocols combine peptides, but stacking CJC-1295 and Icotrokinra has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between CJC-1295 and Icotrokinra?
- CJC-1295 is primarily a performance & growth peptide, while Icotrokinra is used for immune support. CJC-1295 is not FDA-approved; generally classified as a research compound, whereas Icotrokinra is FDA-approved for one or more indications.
- What is CJC-1295 used for?
- Growth hormone, muscle mass, fat loss.
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- Can you take CJC-1295 and Icotrokinra together?
- Some users combine peptides within a single protocol, but stacking CJC-1295 and Icotrokinra has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is CJC-1295 or Icotrokinra FDA-approved?
- CJC-1295 is not FDA-approved; generally classified as a research compound. Icotrokinra is FDA-approved for one or more indications.
Read the full articles
- CJC-1295 — full monograph: mechanism, research, dosing & references
- Icotrokinra — full monograph: mechanism, research, dosing & references